Alto Neuroscience Inc. (ANRO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Alto Neuroscience Inc. (ANRO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.35

-0.09 (-2.03%)

At close: Jan 15, 2025, 3:46 PM

undefined% (undefined)

Bid	4.35
Market Cap	117.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.38
PE Ratio (ttm)	-1.83
Forward PE	n/a
Analyst	Buy

Ask	4.38
Volume	158,756
Avg. Volume (20D)	732,039
Open	4.58
Previous Close	4.44
Day's Range	4.35 - 4.62
52-Week Range	3.56 - 24.00
Beta	undefined

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphod...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 2, 2024

Employees 78

Stock Exchange NYSE

Ticker Symbol ANRO

Website https://www.altoneuroscience.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ANRO stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 221.84% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-69.99%

Alto Neuroscience shares are trading lower after t... Unlock content with Pro Subscription

2 months ago · Source

+1.96%

Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.

News

6 days ago · zacks.com

All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy

Alto Neuroscience, Inc. (ANRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · businesswire.com

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel prec...

2 months ago · businesswire.com

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #AltoNeuroscience--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (“Alto Neur...

2 months ago · businesswire.com

Alto Neuroscience to Participate in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...

2 months ago · benzinga.com

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

On Tuesday, Alto Neuroscience, Inc. ANRO revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo.